Sulfonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: a population-based cohort study.

Sulfonylureas are associated with an increased risk of VA when used as first-line therapy for type 2 diabetes relative to metformin use. This increased risk should be considered when prescribing sulfonylureas as an initial treatment for type 2 diabetes. This article is protected by copyright. All rights reserved.